Cat. No.: HY-N0183

Formononetin

(Synonyms: Biochanin B; Flavosil; Formononetol)

24 Cited Publications

Avis client

Based on 24 publication(s) in Google Scholar

Formononetin is a potent FGFR2 inhibitor with an IC₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.21%
CAS No.: 485-72-3
Formule: C₁₆H₁₂O₄
Masse moléculaire:268.26

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Formononetin Chemical Structure

CAS No.: 485-72-3

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (24)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

Formononetin is a potent FGFR2 inhibitor with an IC₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth^[1].

IC₅₀ & Target^[1]

FGFR2

4.31 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	ED₅₀	2.87 μg/mL Compound: 11	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 8201311]
A549	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18440233]
B16-BL6	IC₅₀	>100 μM Compound: 13	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 18440233]
BV-2	IC₅₀	>100 μM Compound: 19	Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 25466192]
BV-2	IC₅₀	>50 μM Compound: 9	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production	[PMID: 29482940]
BV-2	IC₅₀	13.19 μM Compound: 2	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
DU-145	IC₅₀	>100 μM Compound: Formononetin	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22633834]
ECa-109 cell line	IC₅₀	>100 μM Compound: 1	Cytotoxicity against human EC109 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human EC109 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 28038329]
HCT-116	GI₅₀	64 μM Compound: 12e	Antiproliferative activity against human HCT116 cell line Antiproliferative activity against human HCT116 cell line	[PMID: 16789754]
HCT-116	IC₅₀	60.97 μM Compound: Formononetin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 22633834]
HeLa	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18440233]
HeLa	IC₅₀	8.51 μM Compound: Formononetin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 22633834]
HepG2	IC₅₀	60.5 μM Compound: 15	Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24974349]
HT-1080	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 18440233]
HT-29	ED₅₀	6.43 μg/mL Compound: 11	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 8201311]
HT-29	GI₅₀	74 μM Compound: 12e	Antiproliferative activity against human HT29 cell line Antiproliferative activity against human HT29 cell line	[PMID: 16789754]
Lewis lung carcinoma cell line	IC₅₀	>100 μM Compound: 13	Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay	[PMID: 18440233]
MCF7	ED₅₀	1.96 μg/mL Compound: 11	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 8201311]
MCF7	GI₅₀	81.4 μM Compound: 12e	Antiproliferative activity against human MCF7 cell line Antiproliferative activity against human MCF7 cell line	[PMID: 16789754]
MDA-MB-468	GI₅₀	27.2 μM Compound: 12e	Antiproliferative activity against human MDA-MB-468 cell line Antiproliferative activity against human MDA-MB-468 cell line	[PMID: 16789754]
MDCK	CC₅₀	123 μM Compound: 3	Cytotoxicity against MDCK cells after 72 hrs Cytotoxicity against MDCK cells after 72 hrs	[PMID: 24313801]
MDCK	IC₅₀	38.2 μM Compound: 3	Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24313801]
MDCK	IC₅₀	42.6 μM Compound: 3	Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24313801]
MGC-803	IC₅₀	>100 μM Compound: 1	Cytotoxicity against human MGC803 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 28038329]
N9	IC₅₀	>100 μM Compound: 4	Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 28073678]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	50 μM Compound: 12e	Antiproliferative activity against human NCI60 cell line Antiproliferative activity against human NCI60 cell line	[PMID: 16789754]
PC-3	IC₅₀	57.01 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 28038329]
RAW264.7	IC₅₀	56.1 μM Compound: 6	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 23743282]
SGC-7901	IC₅₀	2.17 μM Compound: Formononetin	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 22633834]
SH-SY5Y	IC₅₀	>100 μM Compound: Formononetin	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 22633834]
U-937	IC₅₀	44 μM Compound: 6, formononetin	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	45 μM Compound: 6, formononetin	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	50 μM Compound: 6, formononetin	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]

In Vitro

Formononetin is one of the major isoflavonoid constituents isolated from Astragalus membranaceus and has been demonstrated diverse pharmacological benefits. Formononetin possesses anti-angiogenic activity in human colon cancer cells. Formononetin also promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells^[1].
Formononetin (25 to 150 μM) markedly decreases the proliferation of endothelial cells stimulated by FGF2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HUVECs
Concentration:

0, 10, 25, 50, 75, 100, and 150 μM
Incubation Time:
Result:

Significantly decreased the proliferation of HUVECs stimulated by FGF2 in a dose-dependent manner, while had little inhibitory effects on HUVECs that were not stimulated by FGF2.

In Vivo

Formononetin dramatically suppresses tumor volumes and the Formononetin-treated group tumor weight are significantly inhibited compared with the vehicle group . Formononetin treatment is well tolerated, and there is no significant difference in weight between vehicle group and formononetin treated groups^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude mice bearing MDA-MB-231 xenografts^[1]
Dosage:

100 mg/kg
Administration:

Treated daily by intragastric administration for 25 days
Result:

Inhibited breast cancer growth and angiogenesis in vivo.

Chemical Information

CAS No. 485-72-3
Appearance Solid
Masse moléculaire 268.26
Formule C₁₆H₁₂O₄
Color White to off-white
SMILES

O=C1C(C2=CC=C(OC)C=C2)=COC3=CC(O)=CC=C13
Synonyms

Biochanin B; Flavosil; Formononetol
Structure Classification
- Flavonoids
- Isoflavones
Initial Source
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (24)

All Histological Imaging/StainingCell Imaging/StainingWBIF

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]

2021 Jan;11(1):143-155. PMID: 33532186
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Phytomedicine

Formononetin mitigates alcoholic liver disease by restoring ALDH2 function and inducing ERK1/2-Nrf2 antioxidant signaling. [Abstract]

2025 Oct 14:148:157408. PMID: 41110354
Phytomedicine

Formononetin, a bioactive isoflavone compound in modified nuanxinkang, alleviates cardiorenal syndrome type 4-induced mitochondrial dysfunction by targeting Hippo-YAP signaling. [Abstract]

2025 Aug 15:147:157152. PMID: 40850069
Phytomedicine

Formononetin enhances cisplatin chemotherapy sensitivity in osteosarcoma by inducing ferroptosis and reconstructing the immune microenvironment. [Abstract]

2025 Jun 9:145:156960. PMID: 40543234

Formononetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jun 9:145:156960. [Abstract]

Formononetin (25-100 mg/kg, i.g.) administration ameliorated Ethanol-Induced liver injury in 12 weeks aged mice. Representative images of H&E staining.

Formononetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jun 9:145:156960. [Abstract]

Formononetin (25-100 mg/kg, i.g.) administration ameliorated Ethanol-Induced liver injury in 12 weeks aged mice. Representative images of TUNEL staining.

Formononetin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jun 9:145:156960. [Abstract]

Formononetin (25-100 mg/kg, i.g.) protected against Ethanol induced aldehyde toxicity in 12 weeks aged mice. Representative images of Dihydroethidium (DHE) staining and 4-Hydroxynonenal (4-HNE) staining.
Mol Med

Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats. [Abstract]

2019 Dec;20(6):4984-4992. PMID: 31702810

Formononetin purchased from MedChemExpress. Usage Cited in: Mol Med. 2019 Dec;20(6):4984-4992. [Abstract]

Formononetin (10-60 mg/kg, i.p., daily for 2 weeks) suppressed Monocrotaline (MCT)-induced pulmonary vascular remodeling in male Sprague-Dawley (7-weeks-old) rats.

Formononetin purchased from MedChemExpress. Usage Cited in: Mol Med. 2019 Dec;20(6):4984-4992. [Abstract]

Formononetin (10-60 mg/kg, i.p., daily for 2 weeks) attenuated decreases in Bax and cleaved caspase-3 expression induced by Monocrotaline (MCT).
Phytother Res

Formononetin improves the inflammatory response and bone destruction in knee joint lesions by regulating the NF-kB and MAPK signaling pathways. [Abstract]

2023 Aug;37(8):3363-3379. PMID: 37002905
Ind Crops Prod

2025 Dec 11;239:122458.
Chin Med

Therapeutic potential of Sheng-Xian-Tang in doxorubicin-induced chronic heart failure by regulation of phenylalanine metabolism disruption. [Abstract]

2026 Jan 12;21(1):29. PMID: 41527105
Am J Chin Med

Formononetin Alleviates Ischemic Acute Kidney Injury by Regulating Macrophage Polarization through KLF6/STAT3 Pathway. [Abstract]

2024;52(5):1487-1505. PMID: 39169449
Int J Mol Sci

Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein. [Abstract]

2024 Aug 2;25(15):8471. PMID: 39126039
Biosci Rep

Experimental evidence and network pharmacology-based analysis reveal the molecular mechanism of Tongxinluo capsule administered in coronary heart diseases. [Abstract]

2020 Oct 30;40(10):BSR20201349. PMID: 32990315
Ann Med

In silico and in vivo verification of the mechanism of formononetin in treating hepatocellular carcinoma. [Abstract]

2024 Dec;56(1):2404550. PMID: 39301883
Fish Shellfish Immunol

Emodin enhances host antiviral immunity against Micropterus salmoides rhabdovirus by activating RLR signaling in largemouth bass. [Abstract]

2025 Aug 6:166:110633. PMID: 40769268
Mol Med Rep

Inhibitory effects of formononetin on the monocrotaline‑induced pulmonary arterial hypertension in rats. [Abstract]

2020 Mar;21(3):1192-1200. PMID: 31922224
Naunyn Schmiedebergs Arch Pharmacol

Mechanism of Sophorae Flavescentis Radix against ovarian cancer via new pharmacology, molecular docking, and experimental verification. [Abstract]

2024 Sep;397(9):6837-6850. PMID: 38561549
Mol Immunol

Formononetin in Jiawei Qihuangyin inhibits podocyte epithelial-mesenchymal transition and ameliorates diabetic nephropathy via SIRT1/NF-κB axis. [Abstract]

2026 Feb:190:1-10. PMID: 41483656
Genomics

Transcriptomics and metabolomics reveal the induction of flavonoid biosynthesis pathway in the interaction of Stylosanthes-Colletotrichum gloeosporioides. [Abstract]

2021 Jul;113(4):2702-2716. PMID: 34111523
Genes (Basel)

Integration of Transcriptomics and WGCNA to Characterize Trichoderma harzianum-Induced Systemic Resistance in Astragalus mongholicus for Defense against Fusarium solani. [Abstract]

2024 Sep 8;15(9):1180. PMID: 39336771
Tissue Cell

Niaodukang for the treatment of chronic kidney disease: Regulation of the TRAF3/NF-κB2 signaling pathway and its improvement of the intestinal barrier. [Abstract]

2025 Dec 9:99:103271. PMID: 41401720
Biochem Biophys Res Commun

Formononetin ameliorates myocardial ischemia/reperfusion injury in rats by suppressing the ROS-TXNIP-NLRP3 pathway. [Abstract]

2020 May 7;525(3):759-766. PMID: 32145915
Biomed Chromatogr

Comparative pharmacokinetic study on three formulations of Astragali Radix by an LC-MS/MS method for determination of formononetin in human plasma. [Abstract]

2019 Sep;33(9):e4563. PMID: 31025385
Phytomed Plus

2023 Sep 1, 100483.

Solvant et solubilité

In Vitro:

DMSO : ≥ 35 mg/mL (130.47 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7277 mL

18.6386 mL

37.2773 mL

5 mM

0.7455 mL

3.7277 mL

7.4555 mL

10 mM

0.3728 mL

1.8639 mL

3.7277 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (9.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (9.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (18.64 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 25 mg/mL (93.19 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Xiao Yu Wu,et al. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget. 2015 Dec 29;6(42):44563-78. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7277 mL	18.6386 mL	37.2773 mL	93.1932 mL
	5 mM	0.7455 mL	3.7277 mL	7.4555 mL	18.6386 mL
	10 mM	0.3728 mL	1.8639 mL	3.7277 mL	9.3193 mL
	15 mM	0.2485 mL	1.2426 mL	2.4852 mL	6.2129 mL
	20 mM	0.1864 mL	0.9319 mL	1.8639 mL	4.6597 mL
	25 mM	0.1491 mL	0.7455 mL	1.4911 mL	3.7277 mL
	30 mM	0.1243 mL	0.6213 mL	1.2426 mL	3.1064 mL
	40 mM	0.0932 mL	0.4660 mL	0.9319 mL	2.3298 mL
	50 mM	0.0746 mL	0.3728 mL	0.7455 mL	1.8639 mL
	60 mM	0.0621 mL	0.3106 mL	0.6213 mL	1.5532 mL
	80 mM	0.0466 mL	0.2330 mL	0.4660 mL	1.1649 mL
	100 mM	0.0373 mL	0.1864 mL	0.3728 mL	0.9319 mL

Keywords

Formononetin

24 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Formononetin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Flavonoids Library

Anti-Lung Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Formononetin

Activité biologique

Chemical Information

Publications (24)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Formononetin Related Classifications

Cat. No.: HY-N0183